<DOC>
	<DOC>NCT00771979</DOC>
	<brief_summary>The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.</brief_summary>
	<brief_title>Relative Bioavailability of Phase II and Phase III Formulations of AZD0530</brief_title>
	<detailed_description />
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Female subjects must be of Non childbearing potential Body mass index between 19 and 30 kg/m2 and weigh between 50100 kg Presence of any clinically significant illness Abnormal vital signs History of any conditions that may put the subject at risk by participating in the study Participation in another clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Relative Bioavailability</keyword>
</DOC>